Skip to content
Cohance Lifesciences
Cohance LifesciencesCohance Lifesciences
  • Home
  • About
    • Our Company
    • Vision and Values
    • Board of Directors, Management & Advisory Council
    • Management Committee
    • Corporate Information
  • Business Units
    • CDMO
    • API and Formulations
    • Clinical research & Bio Analytical Studies
  • Research and Development
  • Infrastructure
    • Overview
    • Manufacturing Units
      • API Unit I – Jaggayapet
      • API Unit II – Atchutapuram
      • API Unit III – Ankaleshwar
      • API Unit IV – Nacharam
      • API Unit V – Parwada, Vizag
      • FDF/PFI Unit I – Nacharam
      • FDF/PFI Unit II – Jadcherla
    • R&D
      • API R&D Unit I – Patancheru
      • API R&D Unit II – Ankaleshwar
      • API R&D Unit III – Nacharam
      • FDF R&D Unit I – Nacharam
    • Clinical Research and Bio Analytical Studies
      • CRBio – Balanagar
  • Sustainability
    • EHS
    • CSR
    • Governance
  • Life at Cohance
    • We are Cohancers
    • Cohance with Us
    • Gallery
  • Investors
  • Media
    • Press release/announcement
    • Media coverage
  • Contact
  • Home
  • About
    • Our Company
    • Vision and Values
    • Board of Directors, Management & Advisory Council
    • Management Committee
    • Corporate Information
  • Business Units
    • CDMO
    • API and Formulations
    • Clinical research & Bio Analytical Studies
  • Research and Development
  • Infrastructure
    • Overview
    • Manufacturing Units
      • API Unit I – Jaggayapet
      • API Unit II – Atchutapuram
      • API Unit III – Ankaleshwar
      • API Unit IV – Nacharam
      • API Unit V – Parwada, Vizag
      • FDF/PFI Unit I – Nacharam
      • FDF/PFI Unit II – Jadcherla
    • R&D
      • API R&D Unit I – Patancheru
      • API R&D Unit II – Ankaleshwar
      • API R&D Unit III – Nacharam
      • FDF R&D Unit I – Nacharam
    • Clinical Research and Bio Analytical Studies
      • CRBio – Balanagar
  • Sustainability
    • EHS
    • CSR
    • Governance
  • Life at Cohance
    • We are Cohancers
    • Cohance with Us
    • Gallery
  • Investors
  • Media
    • Press release/announcement
    • Media coverage
  • Contact

Yearly Archives: 2023

You are here:
  1. Home
  2. 2023

ALL FACILITIES IN GOVERNMENT HOSIPTAL

Media coverageBy cohanceAugust 7, 2023

MODERN EQUIPMENT TO GOVERNMENT HOSPITAL

Media coverageBy cohanceAugust 7, 2023

INSPIRING SERVICES OF COHANCE

Media coverageBy cohanceAugust 7, 2023

Advent International Launches New Brand For Its API Platform

Media coverageBy cohanceJanuary 4, 2023

Private equity investor Advent International, on Tuesday announced the launch of Cohance Lifesciences, a new brand identity for its API (active pharmaceutical ingredient) and CDMO (contract development and manufacturing company) platform. Cohance Lifesciences would help in establishing a unified new brand identity for the API and CDMO platform to better reflect its vision and operating…

Advent International launches new brand for its API platform

Media coverageBy cohanceJanuary 4, 2023

Private equity investor Advent International, on Tuesday announced the launch of Cohance Lifesciences, a new brand identity for its API (active pharmaceutical ingredient) and CDMO (contract development and manufacturing company) platform. Cohance Lifesciences would help in establishing a unified new brand identity for the API and CDMO platform to better reflect its vision and operating…

Advent brings three acquired healthcare firms under Cohance brand

Media coverageBy cohanceJanuary 4, 2023

Cohance Lifesciences intends to add more assets in future, to become one of the top three API and CDMO companies in India Private equity firm, Advent International has launched Cohance Lifesciences to hold its active pharmaceutical ingredients (API) business and contract development and manufacturing organisation (CDMO). Cohance will comprise three formerly acquired companies, RA Chem…

Go to Top